8,748.75-43.45
Stock Analysis, IPO, Mutual Funds, Bonds & More

Sell Glenmark Pharmaceuticals, price target Rs 304: Shubham Aggarwal

The analyst suggested a stoploss at Rs 330 .

ThinkStock Photos|
Last Updated: Feb 07, 2020, 09.14 AM IST
0Comments
Shubham Aggarwal of Quantsapp Advisory has a sell call on Glenmark Pharmaceuticals Ltd. with a target price of Rs 304.0 . The current price of Glenmark Pharmaceuticals Ltd. is Rs 318.65 Time period given by the analyst is Intra Day when Glenmark Pharmaceuticals Ltd. price can reach defined target. . Shubham Aggarwal recommended to keep a stoploss at Rs 330 .

Glenmark Pharmaceuticals Ltd., incorporated in 1977, has a market cap of Rs 8991.29 crore.
Glenmark Pharmaceuticals Ltd. key Products/Revenue Segments include Pharmaceuticals which contributed Rs 6042.06 Crore to Sales Value (93.93 % of Total Sales), Other Operating Revenue which contributed Rs 335.83 Crore to Sales Value (5.22 % of Total Sales) and Sale of services which contributed Rs 54.00 Crore to Sales Value (0.83 % of Total Sales)for the year ending 31-Mar-2018.

For the quarter ended 30-09-2019, the company has reported a Consolidated sales of Rs 2763.73 Crore, up 21.02 % from last quarter Sales of Rs 2283.60 Crore and up 8.81 % from last year same quarter Sales of Rs 2539.86 Crore Company has reported net profit after tax of Rs 255.54 Crore in latest quarter.

The company’s top management includes Dr.Brian W Tempest, Mr.Bernard Munos, Mr.D R Mehta, Mr.Glenn Saldanha, Mr.Julio Ribeiro, Mr.Milind Sarwate, Mr.Rajesh V Desai, Mr.Sridhar Gorthi, Mr.V S Mani, Mrs.B E Saldanha, Mrs.Cherylann Pinto, Ms.Saira Ramasastry. Company has Walker, Chandiok & Co.LLP as its auditors As on 31-12-2019, the company has a total of 282,168,156 shares outstanding.

Also Read

Sell Ashok Leyland, price target Rs 65: Shubham Aggarwal

Buy Jubilant Foodworks, price target Rs 1,910: Shubham Aggarwal

Buy Pidilite Industries, price target Rs 1,650: Shubham Aggarwal

Buy Pidilite Industries, price target Rs 1,625: Shubham Aggarwal

Comments
Add Your Comments
Commenting feature is disabled in your country/region.

Other useful Links


Copyright © 2020 Bennett, Coleman & Co. Ltd. All rights reserved. For reprint rights: Times Syndication Service